Silo pharma announces completion of dosing in safety study of ptsd drug spc-15

Sarasota, fl, july 16, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced completion of dosing in a u.s. food and drug administration (fda)-requested 7-day safety and toxicology large animal study of its lead asset spc-15, and bioanalytical and safety/toxicology results for such study are expected within 60 days.
SILO Ratings Summary
SILO Quant Ranking